Chemo Plus Keytruda Boosts Overall Survival in Advanced TNBC

(MedPage Today) -- Pembrolizumab (Keytruda) plus chemotherapy as first-line treatment significantly improved overall survival (OS) for patients with metastatic triple-negative breast cancer (TNBC) whose tumors express a certain level of PD-L1...